Daniel R. Chevallard - 02 Jan 2026 Form 4 Insider Report for LENZ Therapeutics, Inc. (LENZ)

Reporting relationship: Chief Financial Officer
Issuer ticker: LENZ
Reported as of: 02 Jan 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 06 Jan 2026, 16:21:45 UTC
Prior SEC filing: 07 Nov 2025
Next SEC filing: 30 Mar 2026
Source filing: View source filing
Reporting owner signature: /s/ Daniel R. Chevallard

Key filing fact

Daniel R. Chevallard filed Form 4 for LENZ Therapeutics, Inc. (LENZ) on 06 Jan 2026.

Key facts

This page summarizes Daniel R. Chevallard's Form 4 filing for LENZ Therapeutics, Inc. (LENZ).
2 reported transactions and 2 derivative rows are listed below.
Accepted by SEC: 06 Jan 2026, 16:21.

Change

Previous filing in this sequence was filed on 07 Nov 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001706176 Primary reporting owner

Chevallard Daniel R.

Relationship: Chief Financial Officer
Address: C/O LENZ THERAPEUTICS, INC., 201 LOMAS SANTA FE DRIVE, SUITE 300, SOLANA BEACH
Signature: /s/ Daniel R. Chevallard
Signature date: 06 Jan 2026

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

LENZ transaction Derivative

Stock Option (right to buy)

Award

Transaction value: $0
Shares: +84,200
Change %
Price: $0.000000
Shares after: 84,200
Date: 02 Jan 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 84,200
Exercise price: $16.00
Footnotes: F1

LENZ transaction Derivative

Restricted Stock Unit

Award

Transaction value: $0
Shares: +14,000
Change %
Price: $0.000000
Shares after: 14,000
Date: 02 Jan 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 14,000
Exercise price
Footnotes: F2, F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 3 footnotes

Footnote F1

Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2024 Equity Incentive Plan) through each applicable date, twenty five percent (25%) of the shares subject to the option shall vest on the one (1) year anniversary of the Vesting Commencement Date, and one thirty-sixth (1/36th) of the remaining shares subject to the option shall vest each month thereafter on the same day of the month as the Vesting Commencement Date (and if there is no corresponding day, on the last day of the month). "Vesting Commencement Date" shall mean January 2, 2026.

Footnote F2

Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock.

Footnote F3

Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2024 Equity Incentive Plan) through each applicable date, twenty five percent (25%) of the RSUs subject to the award shall vest on the one (1) year anniversary of the RSU Grant Date, and one eighth (1/8th) of the RSUs subject to the award shall vest every six (6) months thereafter on the same day of the month as the RSU Grant Date (and if there is no corresponding day, on the last day of the month). "RSU Grant Date" shall mean January 2, 2026.